Drug intelligence / Profile preview

BSEM-120

Development stage: Unknown
Lead developer: Nesvik Pharmaceuticals

Overview

BSEM-120 is one of four reformulated drug compounds (BSEM-120, BSEM-125, BSEM-130, BSEM-135) acquired and developed by BioStem Technologies' subsidiary Nesvik Pharmaceuticals in partnership with CCM Pharma Solutions, targeting solid-to-liquid dose conversions via the FDA's 505(b)(2) accelerated approval pathway. Specific details on its active ingredient, mechanism of action, indications, or clinical status remain undisclosed in available sources, positioning it as an early-stage reformulation project focused on regulatory optimization rather than novel discovery.[12][13][14]

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on BSEM-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSEM-120.

Explore the full profile